Telithromycin and the FDA: implications for the future.
Shlaes
David M
DM
Moellering
Robert C
RC
D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D000900:Anti-Bacterial Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D029481:Bronchitis, Chronic / Q000188:drug therapy*; D056486:Chemical and Drug Induced Liver Injury; D017277:Drug Approval; D006801:Humans; D048628:Ketolides / Q000009:adverse effects* / Q000627:therapeutic use; D018570:Risk Assessment; D012852:Sinusitis / Q000188:drug therapy* / Q000382:microbiology; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D048628:Ketolides; C106791:telithromycin